Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 2/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14707175 | 0.83 | MEN1 (0.42) | ACHECHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL22000530 | 0.83 | PRMT3 (0.41) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL25686443 | 0.83 | PRMT3 (0.41) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL19927699 | 0.81 | PRMT3 (0.39) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL381086 | 0.79 | CA14 (0.41) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL19387450 | 0.79 | PRMT3 (0.38) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| SCHEMBL10500332 | 0.79 | RAB9A (0.50) | PRMT1ACHEMEN1KMT2AGAA | |
| SCHEMBL18324399 | 0.78 | CHRNB2 (0.36) | ACHECHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL27467974 | 0.78 | PRMT3 (0.50) | PRMT1PRMT3CARM1PRMT6PRMT8 | |
| Hydrochloric Acid SCHEMBL25181522 | 0.78 | CA14 (0.40) | PRMT1PRMT3CARM1PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111801100-B | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-109641904-B | 7-substituted sulfoxy-purinone compounds for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3865482-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865482-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2020-12-10 | — | — | US | disclosed |
| US-7494714-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2009-02-24 | — | — | US | disclosed |
| US-7494714-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070264505-A1 | Resistant to the adsorption of proteins, cells and bacteria; have a chemical chain bonded thereon that comprise a terminal group free of a hydrogen bond donor or where a hydrogen bond donor is sufficiently buried | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070264505-A1 | Resistant to the adsorption of proteins, cells and bacteria; have a chemical chain bonded thereon that comprise a terminal group free of a hydrogen bond donor or where a hydrogen bond donor is sufficiently buried | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070264505-A1 | Resistant to the adsorption of proteins, cells and bacteria; have a chemical chain bonded thereon that comprise a terminal group free of a hydrogen bond donor or where a hydrogen bond donor is sufficiently buried | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276286-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276286-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276286-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2007-10-02 | — | — | US | disclosed |
| WO-2002006407-A9 | SURFACES THAT RESIST THE ADSORPTION OF BIOLOGICAL SPECIES | HARVARD COLLEGE (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20020102405-A1 | Surfaces that resist the adsorption of biological species | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | PRMT1 523/4885PRMT3 103/4885CARM1 554/4885 |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | FURIN, UGT1A7, SARS1 | PRMT1 369/4885PRMT3 466/4885CARM1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.